A Pharmaceutical Composition Containing An Ace Inhibitor And A Calcium Channel Blocker
Patent No. EP2919815 (titled "A Pharmaceutical Composition Containing An Ace Inhibitor And A Calcium Channel Blocker") was filed by Adamed Pharma on Nov 12, 2013. The application was issued on Sep 6, 2017.
Patent Summary
A stable pharmaceutical composition for treating hypertension comprises a blend of a powder and a granulate that are not physically separated. The powder contains an ACE inhibitor, specifically ramipril, perindopril, or their pharmaceutically acceptable salts, hydrates, and solvates. The granulate contains a calcium channel blocker, specifically amlodipine or its pharmaceutically acceptable salts, hydrates, and solvates. Both components include one or more excipients, such as fillers, binders, disintegrants, and glidants. The composition maintains active substance degradants at pharmaceutically acceptable levels without requiring stabilizing or pH-adjusting agents, minimizing mechanical stress on the ACE inhibitor. The blend can be formulated into unit dosage forms, including tablets, capsules, sachets, pellets, or oral solutions.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
EP2919815
- Application Number
- EP13801824A
- Filing Date
- Nov 12, 2013
- Status
- Opposition Rejected
- Feb 28, 2020
- Publication Date
- Sep 6, 2017
- External Links
- Slate, Register , Google Patents